Gliquidone OGB Dexa

Gliquidone OGB Dexa Uses, Dosage, Side Effects, Food Interaction and all others data.

Gliquidone OGB Dexa is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Gliquidone OGB Dexa is an anti-diabetic drug in the sulfonylurea class. In patients with diabetes mellitus, there is a deficiency or absence of a hormone manufactured by the pancreas called insulin. Insulin is the main hormone responsible for the control of sugar in the blood. Gliquidone OGB Dexa is an antidiabetic medication which is used in those patients with adult maturity onset or non-insulin dependent diabetes (NIDDM). It works by lowering blood sugar levels by stimulating the production and release of insulin from the pancreas. It also promotes the movement of sugar from the blood into the cells in the body which need it.

Gliquidone OGB Dexa
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Gliquidone OGB Dexa
Generic	Gliquidone
Gliquidone Other Names	Gliquidona, Gliquidone, Gliquidonum
Type
Formula	C₂₇H₃₃N₃O₆S
Weight	Average: 527.632 Monoisotopic: 527.209006493
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Indonesia
Last Updated:	September 19, 2023 at 7:00 am

Uses

Gliquidone OGB Dexa is a sulfonylurea drug used in the management of diabetes mellitus type 2.

Used in the treatment of diabetes mellitus type 2.

Gliquidone OGB Dexa is also used to associated treatment for these conditions: Type 2 Diabetes Mellitus

How Gliquidone OGB Dexa works

The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone OGB Dexa likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.